Groupama Asset Managment Reduces Position in DexCom, Inc. (NASDAQ:DXCM)

by · The Cerbat Gem

Groupama Asset Managment decreased its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 99.7% in the fourth quarter, Holdings Channel reports. The fund owned 7,707 shares of the medical device company’s stock after selling 2,843,849 shares during the period. Groupama Asset Managment’s holdings in DexCom were worth $601,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $25,000. Private Trust Co. NA increased its stake in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after acquiring an additional 245 shares during the last quarter. TD Private Client Wealth LLC boosted its position in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 167 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares during the period. Finally, Heck Capital Advisors LLC acquired a new stake in DexCom during the fourth quarter worth about $38,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several analyst reports. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and increased their price target for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Canaccord Genuity Group boosted their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and upped their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

Read Our Latest Stock Report on DXCM

Insiders Place Their Bets

In related news, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the transaction, the chief operating officer now owns 313,497 shares of the company’s stock, valued at $22,063,918.86. This trade represents a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is owned by company insiders.

DexCom Stock Down 9.3 %

DexCom stock opened at $61.80 on Friday. The stock’s 50 day moving average price is $80.72 and its 200 day moving average price is $76.94. DexCom, Inc. has a 1-year low of $61.48 and a 1-year high of $141.99. The company has a market cap of $24.15 billion, a PE ratio of 43.22, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Featured Articles

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).